Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies
<p>Abstract</p> <p>Tumor lysis syndrome (TLS) is widely recognized as a serious adverse event associated with the cytotoxic therapies primarily used in hematologic cancers, such as Burkitt lymphoma and acute lymphoblastic leukemia. In recent years, TLS has been more widely observed...
Main Authors: | McBride Ali, Westervelt Peter |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-12-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://www.jhoonline.org/content/5/1/75 |
Similar Items
-
Efficacy of single-dose rasburicase in the management of tumor lysis syndrome: a case series from a regional cancer center in western India
by: Sandeep R Kukkar, et al.
Published: (2016-01-01) -
Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
by: Joanna Matuszkiewicz-Rowinska, et al.
Published: (2020-09-01) -
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
by: Alakel N, et al.
Published: (2017-02-01) -
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series
by: S M Latha, et al.
Published: (2015-01-01) -
Diagnosis and management of tumor lysis syndrome.
by: Isha Puri, et al.
Published: (2020-05-01)